Print

PCI Biotech Announces Last Patient Included in the Phase I/II Study of PC-A11  
2/23/2011 7:49:12 AM

OSLO, Norway--(BUSINESS WIRE)--PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that it has completed the inclusion of patients in its phase I/II study of its lead candidate PC-A11 in cancer patients.
//-->